ArticleJournal of fish diseases2026
Efficacy Assessment of Montanide GEL 02 PR and Liposome-Based Encapsulation as Adjuvants for an FrpA Subunit Vaccine Against Photobacteriosis in Solea senegalensis.
Article in Journal of fish diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Photobacteriosis is a major threat to marine aquaculture, and the siderophore transporter FrpA represents a promising target for effective subunit vaccine development. In this study, we evaluated Montanide GEL 02 PR and phosphatidylcholine-based liposomes as aqueous and safer alternatives to Freund's adjuvant for an FrpA-based subunit vaccine in Solea senegalensis. Fish were immunized with recombinant FrpA formulated with either adjuvant, and induction of FrpA-specific IgM antibody levels was measured. Vaccine efficacy was subsequently assessed by analysis of innate immune gene expression following early pathogen exposure and by survival analysis after infection challenge. Vaccination with rFrpA-Montanide GEL 02 PR induced the highest levels of specific IgM antibodies and conferred strong protection against photobacteriosis, achieving survival rates comparable to those reported for bacterin-based vaccines. This formulation also promoted a rapid and coordinated up-regulation of immune-related genes, including transferrin (tf), lysozyme C1 (lysC1), and complement components C1q and C7. In contrast, rFrpA encapsulated in liposomes elicited weaker immune responses and limited protection. Overall, our results demonstrate that an FrpA-based subunit vaccine formulated with Montanide GEL 02 PR represents a promising strategy for controlling photobacteriosis in aquaculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.